Brief: Ipsen FY 2024 Total Sales Growth Of 9.9% At Cer, 8.7% Reported
Feb 13 (Reuters) - Ipsen SA IPN.PA :
* FY 2024 TOTAL SALES GROWTH OF 9.9% AT CER, 8.7% REPORTED
* FY 2024 CORE OPERATING INCOME OF €1,109M, GROWING 10.8%
* FINANCIAL GUIDANCE: FOR 2025 INCLUDING TOTAL SALES GROWTH
GREATER THAN 5.0%3 AT CER
* FINANCIAL GUIDANCE FOR 2025: CORE OPERATING MARGIN GREATER
THAN
30.0% OF TOTAL SALES
Source text: ID:nGNE7K1qc
Further company coverage: IPN.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients